S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
These cryptos could skyrocket by January (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
These cryptos could skyrocket by January (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
These cryptos could skyrocket by January (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
These cryptos could skyrocket by January (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
OTCMKTS:MEOBF

Mesoblast (MEOBF) Stock Price, News & Analysis

$0.17
0.00 (0.00%)
(As of 02/21/2024 ET)
Today's Range
$0.17
$0.17
50-Day Range
$0.10
$0.17
52-Week Range
$0.10
$1.00
Volume
N/A
Average Volume
37,980 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MEOBF stock logo

About Mesoblast Stock (OTCMKTS:MEOBF)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

MEOBF Stock Price History

MEOBF Stock News Headlines

Jefferies Keeps Their Buy Rating on Mesoblast Limited (MEOBF)
Shocking Bank Secret of the Ultra-Rich
A 229-year-old banking secret is behind some of the wealthiest, most powerful dynasties in American history –  here's how it could help you in 2024.
Mesoblast Ltd ADR MESO
Mesoblast Teva Starts
Mesoblast Limited (MESO) Q4 2022 Earnings Call Transcript
Shocking Bank Secret of the Ultra-Rich
A 229-year-old banking secret is behind some of the wealthiest, most powerful dynasties in American history –  here's how it could help you in 2024.
MindMed Appoints Schond L. Greenway As CFO
Mesoblast reports FQ3 results
Why Mesoblast Stock Is Plunging After Q4 Earnings Report?
See More Headlines
Receive MEOBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:MEOBF
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Silviu Itescu FACP (Age 67)
    FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
    Comp: $734.12k
  • Dr. Eric A. Rose M.D. (Age 73)
    Chief Medical Officer & Executive Director
    Comp: $621.55k
  • Mr. Andrew Chaponnel B.Com.
    Interim Chief Finance Officer
  • Mr. Peter T. Howard B.Sc. (Age 56)
    L.L.B., LLB (Hons), General Counsel & Corporate Executive
  • Mr. Roger D. Brown BA
    Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster BSc (Age 47)
    M.B.A., MS, Head of Pharma Partnering
  • Ms. Geraldine Storton B.Sc.
    M.B.A., MMS, Head of Regulatory Affairs & Quality Management
  • Mr. Justin Horst B.S.
    Head of Manufacturing
  • Ms. Niva Sivakumar B.Com.
    L.L.B., Joint Company Secretary
  • Mr. Paul Hughes BPHARM
    Joint Company Secretary














MEOBF Stock Analysis - Frequently Asked Questions

How have MEOBF shares performed in 2024?

Mesoblast's stock was trading at $0.1667 at the beginning of the year. Since then, MEOBF stock has increased by 0.0% and is now trading at $0.1667.
View the best growth stocks for 2024 here
.

Are investors shorting Mesoblast?

Mesoblast saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 11,000 shares, a decline of 96.5% from the December 31st total of 315,000 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.
View Mesoblast's Short Interest
.

How do I buy shares of Mesoblast?

Shares of MEOBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MEOBF) was last updated on 2/22/2024 by MarketBeat.com Staff